enow.com Web Search

  1. Ads

    related to: pamrevlumab ipf

Search results

  1. Results from the WOW.Com Content Network
  2. Pamrevlumab - Wikipedia

    en.wikipedia.org/wiki/Pamrevlumab

    Pamrevlumab (INN; [1] development code FG-3019) is a humanized monoclonal antibody designed for the treatment of idiopathic pulmonary fibrosis and pancreatic cancer. It binds to the connective tissue growth factor (CTGF) protein. [2] This drug was developed by FibroGen, Inc. [3]

  3. List of therapeutic monoclonal antibodies - Wikipedia

    en.wikipedia.org/wiki/List_of_therapeutic...

    Pamrevlumab [12] mab: human: connective tissue growth factor (CTGF) idiopathic pulmonary fibrosis (IPF), pancreatic cancer Panitumumab [69] Vectibix: mab: human: epidermal growth factor receptor (EGFR) Y: colorectal cancer: Pankomab: mab: humanized: tumor specific glycosylation of MUC1: ovarian cancer Panobacumab [98] mab: human: Pseudomonas ...

  4. Idiopathic pulmonary fibrosis - Wikipedia

    en.wikipedia.org/wiki/Idiopathic_pulmonary_fibrosis

    Idiopathic pulmonary fibrosis (IPF) synonymous with cryptogenic fibrosing alveolitis [5] is a rare, progressive illness of the respiratory system, characterized by the thickening and stiffening of lung tissue, associated with the formation of scar tissue.

  5. Carlumab - Wikipedia

    en.wikipedia.org/wiki/Carlumab

    Clinical trials for Carlumab include studies of idiopathic pulmonary fibrosis, [8] [9] castration-resistant metastatic prostate cancer [1] [10] and solid tumors. [ 11 ] [ 12 ] Carlumab was being developed by Janssen Biotech prior to discontinuation in 2012 [ 13 ] due to limited success in clinical trials.

  6. Fresolimumab - Wikipedia

    en.wikipedia.org/wiki/Fresolimumab

    As of June 2011 the drug was being tested in humans (clinical trials) against IPF, renal disease, and cancer. [ 7 ] [ 8 ] On 13 August 2012, Genzyme applied to begin a Phase 2 clinical trial in primary focal segmental glomerulosclerosis [ 9 ] comparing fresolimumab versus placebo .

  7. Garadacimab - Wikipedia

    en.wikipedia.org/wiki/Garadacimab

    Garadacimab is an experimental human monoclonal antibody under investigation for the treatment of hereditary angioedema. [1] Garadacimab is a monoclonal antibody against the activated coagulation factor XIIa (FXIIa), with potential anti-inflammatory and anticoagulant activities.

  1. Ads

    related to: pamrevlumab ipf